Treace Medical Concepts (TMCI) Stock Price, News & Analysis

Company Overview

Treace Medical Concepts, Inc. is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company’s flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S. Food and Drug Administration and is supported by clinical evidence demonstrating its effectiveness for patients with moderate to severe bunion deformities. Treace works closely with a network of foot and ankle surgeons, offering hands-on training programs and educational resources to facilitate proper adoption of its technology in hospital and ambulatory surgery center settings. In addition to bunion correction, the company continues to explore adjacent applications in foot and ankle reconstruction.

Founded in 2017 and headquartered in Ponte Vedra Beach, Florida, Treace Medical Concepts initially built its commercial presence in North America and is evaluating opportunities for international expansion. The company’s management team brings together experienced medical device executives, orthopedic surgeons, and industry veterans committed to advancing the standard of care in foot and ankle surgery. Treace continues to invest in research and development as it seeks to broaden its product portfolio and drive long-term growth in the orthopedic market.

Key Stats

• Today's Range: $1.84 to $1.97
• 50-Day Range: $1.20 to $2.23
• 52-Week Range: $1.17 to $7.78
• Volume: 47,514 shs
• Average Volume: 783,321 shs
• Market Capitalization: $124.06 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.77
• Consensus Rating: Reduce

Treace Medical Concepts Stock Analysis - MarketRank™

Treace Medical Concepts scored higher than 33% of companies evaluated by MarketBeat, and ranked 689th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Reduce

Consensus Rating

Treace Medical Concepts has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 2 sell ratings.

Upside Potential

Treace Medical Concepts has a consensus price target of $4.77, representing about 152.0% upside from its current price of $1.89.

Amount of Analyst Coverage

Treace Medical Concepts has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Treace Medical Concepts are expected to remain at ($0.92) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Treace Medical Concepts is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Treace Medical Concepts is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Treace Medical Concepts has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for TMCI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Treace Medical Concepts does not currently pay a dividend.

Dividend Growth

Treace Medical Concepts does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.27

News Sentiment

Treace Medical Concepts has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Treace Medical Concepts this week, compared to 4 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Treace Medical Concepts insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.42% of the stock of Treace Medical Concepts is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.08% of the stock of Treace Medical Concepts is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TMCI Stock Analysis - Frequently Asked Questions

How have TMCI shares performed this year?

Treace Medical Concepts' stock was trading at $2.45 on January 1st, 2026. Since then, TMCI stock has decreased by 22.7% and is now trading at $1.8930.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its quarterly earnings data on Friday, February, 27th. The company reported ($0.15) EPS for the quarter, meeting analysts' consensus estimates of ($0.15). The company had revenue of $62.52 million for the quarter, compared to analysts' expectations of $61.76 million. Treace Medical Concepts had a negative net margin of 27.74% and a negative trailing twelve-month return on equity of 59.91%.
Read the conference call transcript.

When did Treace Medical Concepts IPO?

Treace Medical Concepts (TMCI) raised $180 million in an IPO on Thursday, April 22nd 2021. The company issued 11,250,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Who are Treace Medical Concepts' major shareholders?

Treace Medical Concepts' top institutional investors include Abel Hall LLC (0.06%), Hsbc Holdings PLC (0.05%) and Chicago Partners Investment Group LLC (0.04%). Insiders that own company stock include John T Treace, James T Treace, Richard W Mott, Sean F Scanlan, Deepti Jain and F Barry Bays.
View institutional ownership trends.

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Treace Medical Concepts own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Treace Medical Concepts investors own include American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), Waste Connections (WCN), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 2/27/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:TMCI
• CIK: 1630627
• Web: www.treace.com
• Phone: 904-373-5940
• Fax: N/A
• Employees: 250
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Treace Medical Concepts: $4.77
• High Price Target: $7.00
• Low Price Target: $3.00
• Potential Upside/Downside: +150.4%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$59 million
• Net Margins: -27.74%
• Pretax Margin: -27.74%
• Return on Equity: -59.91%
• Return on Assets: -28.44%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 4.31
• Quick Ratio: 3.13

Sales & Book Value

• Annual Sales: $212.69 million
• Price / Sales: 0.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.37 per share
• Price / Book: 1.39

Miscellaneous

• Outstanding Shares: 64,784,000
• Free Float: 49,612,000
• Market Cap: $123.41 million
• Optionable: Optionable
• Beta: 1.10